Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
ROSELAND, N.J., March 21, 2017 -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2016, on Wednesday, March 29, 2017, at 8:30 AM ET. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 90730730.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Wednesday, March 29, 2017 at 11:30 AM ET through 11:30 AM ET on April 05, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 90730730.
About Emisphere
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected]
